Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Japan Govt to Push Ahead with Off-Year Survey, Considering COVID-19 Impact to Decide on Re-Pricing
July 16, 2020
- Japan Govt Maps Out Action Strategy for Regulatory Harmonization in Asia
July 15, 2020
- Health Minister Asks Makers to Boost Syringe, Needle Production for Coronavirus Vaccines
July 15, 2020
- Coronavirus-Neutralizing Antibodies Detected in Japan for 1st Time
July 15, 2020
- Japan Govt to Tweak Honebuto Text for Off-Year Re-Pricing, but Still Holds to Original Plan
July 15, 2020
- LDP Lawmakers Irked as Govt Stands Fast on Off-Year Re-Pricing/Survey Plan; Honebuto Text Tweak Unclear
July 10, 2020
- MHLW’s OTC Panel Begins Discussions toward Interim Report; to Seek Solutions for Problems in Switch-OTC Approval
July 10, 2020
- Original Plan Remains Unchanged for Off-Year Drug Re-Pricing, Survey: Minister
July 9, 2020
- AnGes’ COVID-19 Vaccine Given Some Safety Confirmation Before Clinical Trial: MHLW Official
July 9, 2020
- LDP Lawmakers’ League to Launch Group to Protect People against HPV
July 8, 2020
- MHLW Set to Approve Label Expansions for Kadcyla, Keytruda, Imfinzi and More
July 7, 2020
- Japan Govt Likely to Stick to 2020 Off-Year Drug Re-Pricing Plan in Honebuto Paper
July 6, 2020
- Create Cross-Bureau Scheme at MHLW to Fuel Rx-to-OTC Switches: Regulatory Reform Panel
July 6, 2020
- MHLW Donates Nearly 200 Million Yen to GARDP to Combat Antimicrobial Resistance
July 6, 2020
- Key MOF Panel Passes on Typical Budget Recommendation amid COVID-19
July 3, 2020
- Ruling Parties Call for Careful Discussions on Off-Year Drug Re-Pricing
July 3, 2020
- MHLW to Report Approval Plan for Otsuka Pharmaceutical Factory’s Infusion Solution on July 15
July 3, 2020
- LDP Generic Study Group Urges Govt to Restructure Drug Supply Chain
July 1, 2020
- LDP Study Group Calls for Budgets to Accelerate Genome Analysis Project
July 1, 2020
- Specific Vaccine Negotiations with AstraZeneca about to Start: Minister
July 1, 2020
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…